344 related articles for article (PubMed ID: 19582491)
1. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
2. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
4. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
5. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
6. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.
Del Sindaco D; Pulignano G; Minardi G; Apostoli A; Guerrieri L; Rotoloni M; Petri G; Fabrizi L; Caroselli A; Venusti R; Chiantera A; Giulivi A; Giovannini E; Leggio F
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):324-9. PubMed ID: 17443097
[TBL] [Abstract][Full Text] [Related]
9. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A
Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266
[TBL] [Abstract][Full Text] [Related]
11. Pharmaco-economics of levosimendan in cardiology: a European perspective.
Nieminen MS; Buerke M; Parissis J; Ben-Gal T; Pollesello P; Kivikko M; Karavidas A; Severino P; Comín-Colet J; Wikström G; Fedele F
Int J Cardiol; 2015 Nov; 199():337-41. PubMed ID: 26241640
[TBL] [Abstract][Full Text] [Related]
12. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Graudins A; Najafi J; Rur-SC MP
Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
[TBL] [Abstract][Full Text] [Related]
14. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
15. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.
Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH
Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of score parameters of the Simplified Acute Physiology Score (SAPS)-II for the duration of treatment of intensive care patients].
Schuster HP; Wilts S; Ritschel P; Schuster FP
Wien Klin Wochenschr; 1996; 108(15):462-6. PubMed ID: 8967089
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
20. [Is early discharge possible in patients with uncomplicated heart failure? Cost-efficacy analysis].
Valle R; Canali C; Giovinazzo P; D'Atri M; Milani L
Ital Heart J Suppl; 2003 Dec; 4(12):965-72. PubMed ID: 14976862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
